Ignite Creation Date:
2025-12-24 @ 9:56 PM
Ignite Modification Date:
2025-12-25 @ 7:34 PM
Study NCT ID:
NCT03526432
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-24
First Post:
2018-05-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Sponsor:
University of Oklahoma
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-08-08
Start Date Type:
ACTUAL
Primary Completion Date:
2026-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-09
Completion Date Type:
ESTIMATED
First Submit Date:
2018-05-03
First Submit QC Date:
None
Study First Post Date:
2018-05-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-22
Last Update Post Date:
2025-10-24
Last Update Post Date Type:
ESTIMATED